Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,917
  • Shares Outstanding, K 3,276
  • Annual Sales, $ 90 K
  • Annual Income, $ -13,960 K
  • EBIT $ -12 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.26
  • Price/Sales 20.51
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.44
  • Most Recent Earnings $-0.44 on 03/27/26
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.08
  • Number of Estimates 1
  • High Estimate $-1.08
  • Low Estimate $-1.08
  • Prior Year $-5.00
  • Growth Rate Est. (year over year) +78.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5300 +10.38%
on 03/30/26
1.6200 -63.89%
on 03/18/26
-0.3226 (-35.54%)
since 02/27/26
3-Month
0.5300 +10.38%
on 03/30/26
1.8799 -68.88%
on 02/05/26
-0.6650 (-53.20%)
since 12/26/25
52-Week
0.5300 +10.38%
on 03/30/26
36.0000 -98.38%
on 04/07/25
-11.5150 (-95.17%)
since 03/28/25

Most Recent Stories

More News
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.5850 (+6.17%)
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Closing of its Rights Offering

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
The State Fair of Texas Extends Partnership with accesso® Through 2030, Embracing Innovation and Guest Convenience

ORLANDO, Fla. , Feb. 24, 2026 /PRNewswire/ --  accesso Technology Group  (AIM: ACSO), the leading technology partner to the leisure and entertainment industry, today announced the renewal...

AIM : 0.5850 (+6.17%)
The State Fair of Texas Extends Partnership with accesso® Through 2030, Embracing Innovation and Guest Convenience

ORLANDO, Fla. , Feb. 24, 2026 /CNW/ --  accesso Technology Group  (AIM: ACSO), the leading technology partner to the leisure and entertainment industry, today announced the renewal...

AIM : 0.5850 (+6.17%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.6451
2nd Resistance Point 0.6151
1st Resistance Point 0.6000
Last Price 0.5850
1st Support Level 0.5549
2nd Support Level 0.5249
3rd Support Level 0.5098

See More

52-Week High 36.0000
Fibonacci 61.8% 22.4505
Fibonacci 50% 18.2650
Fibonacci 38.2% 14.0795
Last Price 0.5850
52-Week Low 0.5300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.